CAlgary SAlt for POTS
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT05924646, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Calgary
- Trial code
- NCT05924646
- Record updated
- 7 May 2026
- Original description
Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend ~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.Read full original descriptionShow less
CAlgary SAlt for Postural Orthostatic Tachycardia Syndrome Study
Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend ~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.
Inclusion: Physician Diagnosis of POTS as defined by the CCS Consensus Statement and as follows:; Sustained, excessive orthostatic tachycardia ≥ 30 bpm within 10 minutes standing; Absence of orthostatic hypotension (>20/10 mmHg decrease) within 3 minutes standing; Chronic orthostatic symptoms that improve with recumbence; Age 18-60 years old; Ability to attend the Calgary Autonomic Research Clinic in Calgary; Resident of Canada.
Exclusion: Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication effects, recreational drug effects, and prolonged bedrest; Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies; Patients who have received IV saline in the 2 months preceding the study or who plan to receive it during the course of the study; Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease); Participants with somatization or severe anxiety symptoms will be excluded; Pregnant (self-reported); Fludrocortisone use (due to effects on renal Na+ handling).